Jamaica Approves Ozempic For Local Distribution


Date:

(MENAFN- Caribbean News Global) By Serena Grant

KINGSTON, Jamaica, (JIS) – Ozempic, a prescription medication used to treat Type 2 diabetes and support weight loss, has been approved for distribution on the island as the Government moves to expand treatment options for obesity.

Minister of health and wellness, Dr Christopher Tufton, disclosured while addressing the launch of the ministry's Lifestyle Clinic at the Sandy Bay Health Centre in Hanover on November 12.

Ozempic helps to control blood sugar levels and promote weight loss by reducing appetite and slowing digestion. It is usually administered through a once-weekly injection.

Dr Tufton said that other branded medications to manage obesity are being considered for approval.

“We hope that by next year, they will be approved, and also the generic equivalent to those,” he said, noting that the medications will be available through pharmacies.

The minister noted that persons seeking obesity treatment have been purchasing these medications informally, including from overseas, often at higher prices.

Meanwhile, Dr Tufton said that the Lifestyle Clinic will target persons whose health is at risk due to obesity.

Patients will be referred to the clinic by doctors after medical assessment and will get support from specialists, including psychologists, nutritionists, physical activity specialists and social workers, to assist them in making healthier lifestyle choices and reduce their risk of serious illnesses.

The minister cautioned that medication should not be viewed as a replacement for healthy lifestyle practices, emphasising that managing obesity calls for a broader approach which includes proper nutrition, exercise and medical supervision.

MENAFN17112026000232011072ID1111979463


Caribbean News Global

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search